At the early stages of dementia devoid of Aβ accumulation in the brain, nose-to-brain delivery of L-penetratin/insulin appeared to have the therapeutic effect by preventing the mild cognitive dysfunction of early dementia, whereas it did not prevent severe recognitive dysfunction (Kamei et al., 2017). The gene discussed is INS; the disease is dementia.